X

Trial Profile

Safety of Disease Modifying Antirheumatic Drug (DMARD) and Biologic Treatment of Rheumatoid Arthritis.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
Indications Rheumatoid arthritis
Focus Adverse reactions
Acronyms RALLY
Sponsors Bristol-Myers Squibb

Most Recent Events

17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
07 Dec 2016 Status changed from active, no longer recruiting to completed.
13 Jun 2015 Preliminary safety results presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com